Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia

Myelodysplastic syndromes and acute myeloid leukemia with TP53 mutations are characterized by frequent relapses, poor or short responses, and poor survival with the currently available therapies including chemotherapy and 5-azacitidine (AZA). PRIMA-1(Met)(APR-246,APR) is a methylated derivative of P...

Descripción completa

Detalles Bibliográficos
Autores principales: Maslah, Nabih, Salomao, Norman, Drevon, Louis, Verger, Emmanuelle, Partouche, Nicolas, Ly, Pierre, Aubin, Philippe, Naoui, Nadia, Schlageter, Marie-Helene, Bally, Cecile, Miekoutima, Elsa, Rahmé, Ramy, Lehmann-Che, Jacqueline, Ades, Lionel, Fenaux, Pierre, Cassinat, Bruno, Giraudier, Stephane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271596/
https://www.ncbi.nlm.nih.gov/pubmed/31488557
http://dx.doi.org/10.3324/haematol.2019.218453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271596/
https://www.ncbi.nlm.nih.gov/pubmed/31488557
http://dx.doi.org/10.3324/haematol.2019.218453

Ejemplares similares